BioLife Solutions (NASDAQ:BLFS) Announces Earnings Results

BioLife Solutions (NASDAQ:BLFS) posted its quarterly earnings results on Monday. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32, RTT News reports. The company had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter last year, the firm posted ($0.21) earnings per share. BioLife Solutions updated its FY 2025 guidance to EPS.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $24.51 on Tuesday. BioLife Solutions has a 52 week low of $14.84 and a 52 week high of $29.55. The company has a market cap of $1.14 billion, a PE ratio of -23.12 and a beta of 1.91. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The company’s fifty day simple moving average is $26.74 and its 200-day simple moving average is $25.50.

Analyst Ratings Changes

BLFS has been the topic of a number of recent analyst reports. Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. TD Cowen increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Craig Hallum increased their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. KeyCorp increased their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.43.

Insider Buying and Selling

In related news, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. The trade was a 2.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Troy Wichterman sold 987 shares of BioLife Solutions stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,009 shares of company stock valued at $272,594 in the last quarter. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.